2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Neeta Somaiah, MD, discusses remaining challenges in soft tissue sarcoma.
Neeta Somaiah, MD, associate professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses remaining challenges in soft tissue sarcoma.
Due to the number of sarcoma subtypes, defining the optimal treatment for patients with soft tissue sarcoma remains an ongoing challenge, says Somaiah.
Additionally, other factors such as the degree of responsiveness and the likelihood of recurrence could also inform treatment selection, Somaiah explains. Notably, many institutions have their own approach to adjuvant therapy.
In recent years, significant advances have been made in the advanced/metastatic setting; however, there is still room for improvement. Future research should include more subtype-specific trials to better define which patient populations should receive targeted therapy, Somaiah concludes.
Related Content: